1 / 82

Myelodysplastic syndrome and acute myeloid leukaemia

Myelodysplastic syndrome and acute myeloid leukaemia. Dr. Edmond S. K. Ma Division of Haematology Department of Pathology The University of Hong Kong. Leukaemia classification. FAB MIC 1987 EGIL 1996 REAL Proposed by ILSG in 1994

zahur
Télécharger la présentation

Myelodysplastic syndrome and acute myeloid leukaemia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Myelodysplastic syndrome and acute myeloid leukaemia Dr. Edmond S. K. Ma Division of Haematology Department of Pathology The University of Hong Kong

  2. Leukaemia classification • FAB • MIC 1987 • EGIL 1996 • REAL • Proposed by ILSG in 1994 • Lymphoma classification, but principles extended to other haemic neoplasms • Encompasses all available information • Consensus approach

  3. WHO Classification • Collaborative project of: • European Association for Haematopathology • Society for Haematopathology • Started in 1995 • Steering Committee • Working Group Meeting in Lyon, France, November 8 – 11, 2000 • Clinical Advisory Committee

  4. Myelodysplastic syndrome • A group of clonal haemopoietic stem cell disorder characterized by dysplasia and ineffective haemopoiesis in one or more major myeloid cell line • < 20% blasts in blood and bone marrow

  5. Myelodysplastic syndrome • A disease of the elderly • Incidence : 3 – 20 /100,000 • Increasing number of therapy related MDS • Clinical features: related to cytopenia • Etiology: prior chemoradiotherapy, benzene exposure, cigarette smoking, inherited syndromal disorders (e.g. Fanconi’s anaemia)

  6. Dyserythropoiesis • Nuclear budding • Inter-nuclear bridging • Karyorrhexis • Multinuclearity • Megaloblastoid maturation • Ringed sideroblast • Vacuolation • PAS +ve

  7. Dyserythropoiesis

  8. Dyserythropoiesis

  9. Dysgranulopoiesis • Small size • Nuclear hypolobulation (pseudo-Pelger Heut) • Hypersegmentation • Hypogranularity • Pseudo-Chediak Higashi granules

  10. Dysgranulopoiesis

  11. Dysgranulopoiesis

  12. Dysmegakaryocytopoiesis • Hypolobulated micro-megakaryocyte • Non-lobulated nuclei in megakaryocyte of all sizes • Multiple, widely separated nuclei

  13. Megakaryocyte dysplasia

  14. Megakaryocyte dysplasia

  15. Abnormal localization of immature precursors • Presence of 3 or more small clusters of myeloblasts and promyelocytes (5 – 8 cells) in marrow trephine biopsy in the central portion of the marrow away from the vascular structure and the endosteal surface of the bone trabeculae

  16. Abnormal localization of immature precursors

  17. Genetics • 5q- syndrome • del (17p), small hypolobulated or vacuolated neutrophils, p53 mutations, poor prognosis • -5/5q- • -7/7q- • del(20q) • 3q21q26 abnormality

  18. Cytogenetics and prognosis • Good risk • Normal, isoloted 5q-, isolated 20q-, -Y • Poor risk • Complex changes (> 3 abnormalities) • Chromosome 7 abnormalities • Intermediate risk • All other changes

  19. International Prognostic Scoring System Score00.511.5 • % blasts <5 5-10 - 11-20 • Karyotype Good Intermediate Poor • Cytopenia 0-1 2-3 • Cytopenia: Hb < 10 g/dL; neutrophils < 1.5 X 109/L; plt < 100 X 109/L • Risk groups Low = 0; Intermediate-1 = 0.5-1; Intermediate-2 = 1.5-2; High = 2.5

  20. PB anaemia, no or rare (<1%) blasts MB Unilineage dysplasia, restricted to erythroid lineage, < 5% blasts, < 15% ringed sideroblasts Refractory anaemia

  21. Refractory anaemia • Exclusion of known secondary causes of dyserythropoiesis • If no cytogenetic abnormality present, reassess after 6 months • Protracted clinical course, median survival is 66 months, leukaemic transformation 6%

  22. Giant pronormoblast is parvovirus infection

  23. PB Anaemia No blast MB  15% ringed sideroblasts Erythroid dysplasia only <5% blasts Refractory anaemia with ringed sideroblasts

  24. Ringed sideroblast • Erythroid precursor • One third or more of the nucleus • Encircled by 10 or more siderotic granules

  25. Refractory anaemia with ringed sideroblasts • Indolent clinical course • Median survival = 6 years • Leukaemic transformation 1 – 2 %

  26. PB Bicytopenia or pancytopenia No or rare blasts No Auer rod < 1 X 109/L monocytes MB Dysplasia in  10% of cells in two or more myeloid cell lines < 5% blasts No Auer rod < 15% ringed sideroblasts Refractory cytopenia with multilineage dysplasia

  27. Refractory cytopenia with multilineage dysplasia

  28. Refractory cytopenia with multilineage dysplasia

  29. Refractory cytopenia with multilineage dysplasia

  30. PB Bicytopenia or pancytopenia No or rare blasts No Auer rod < 1 X 109/L monocytes MB Dysplasia in  10% of cells in two or more myeloid cell lines < 5% blasts No Auer rod  15% ringed sideroblasts Refractory cytopenia with multilineage dysplasia and ringed sideroblasts

  31. Refractory cytopenia with multilineage dysplasia • Cytogenetic abnormality seen in 50% +8 Monosomy 7 del(7q) Monosomy 5 del (5q) del (20q) Complex karyotype

  32. Refractory cytopenia with multilineage dysplasia • Leukaemic transformation 11% • Overall median survival 33 months • RCMD and RCMD-RS are similar in clinical course • Patients with complex karyotype have similar clinical course to RAEB

  33. PB Cytopenia <5% blasts No Auer rod <1% monocytes MB Unilineage or multilineage dysplasia 5-9% blasts No Auer rod Refractory anaemia with excess blasts-1

  34. PB Cytopenia 5-19 % blasts Auer rod ± <1% monocytes MB Unilineage or multilineage dysplasia 10-19% blasts Auer rod ± Refractory anaemia with excess blasts-2

  35. Refractory anaemia with excess blasts-2

  36. Refractory anaemia with excess blasts • Blast cells show myeloid phenotype • Leukaemic transformation • RAEB-1 25% • RAEB-2 33% • Median survival • RAEB-1 18 months • RAEB-2 10 months

  37. PB Cytopenias No or rare blasts No Auer rods MB Unilineage dysplasia, one myeloid cell line (non-erythroid) <5% blasts No Auer rod Myelodysplastic syndrome, unclassifiable

  38. PB Anaemia Usually normal or increased platelet count <5% blasts MB Normal or increased megakaryocytes with hypolobulated nuclei <5% blasts Isolated 5q- abnormality No Auer rod 5q- syndrome

  39. 5q- syndrome

  40. Acute myeloid leukaemia • Acute myeloid leukaemia with recurrent genetic abnormalities • Acute myeloid leukaemia with multilineage dysplasia • Acute myeloid leukaemia and myelodysplastic syndrome, therapy-related • Acute myeloid leukaemia not otherwise categorized

  41. Acute myeloid leukaemia

  42. Acute myeloid leukaemia

  43. Acute myeloid leukaemia • The blast % is lowered from 30% (FAB) to 20% (WHO) • Median age of onset = 60 yrs • Incidence 4 –10 / 100,000 • Etiology

  44. Myeloblasts versus lymphoblasts

  45. Acute myeloid leukaemia

  46. Acute lymphoblastic leukaemia

  47. Acute myeloid leukaemia: cytochemistry Myeloperoxidase Sudan Black B Non-specific esterase a-naphthyl butyrate a-naphthyl acetate

  48. Cytochemistry: MPO

  49. Cytochemistry: NSE

  50. Cytochemistry

More Related